India & Brazil Sign Pharma MoU to Boost Medical Product Regulation

India and Brazil have exchanged a Memorandum of Understanding to strengthen bilateral cooperation in regulating pharmaceutical and medical products. The agreement was signed between India's CDSCO and Brazil's ANVISA in the presence of both countries' leaders. It establishes a framework for information sharing and regulatory convergence to ensure the availability of safe, quality-assured medicines. The MoU is expected to bolster supply chains and foster collaboration in health technologies between the two major Global South partners.

Key Points: India-Brazil MoU on Pharmaceutical Regulation Cooperation

  • Structured framework for regulatory cooperation
  • Aims for safe, effective medicines
  • Enhances bilateral health sector ties
  • Strengthens medical product supply chains
2 min read

India-Brazil exchange MoU to strengthen cooperation in pharmaceutical and medical products regulation

India and Brazil exchange MoU to strengthen cooperation in regulating pharmaceuticals and medical devices, enhancing safety and supply chains.

"promote convergence in regulatory practices - Official Release"

New Delhi, Febraury 22

India and Brazil exchanged a Memorandum of Understanding to strengthen bilateral cooperation in the field of regulation of pharmaceutical and medical products.

The MoU was exchanged between India's Central Drugs Standard Control Organisation (CDSCO) and Brazilian Health Regulatory Agency (ANVISA), marking an important step towards deeper regulatory collaboration between the two countries, according to a release.

Director-President of ANVISA, Leandro Safatle and Indian Ambassador to Brazil, Dinesh Bhatia, exchanged the MoU today in Hyderabad House in the presence of Narendra Modi, Prime Minister of India and Luiz Inacio Lula da Silva, President of Brazil.

The MoU establishes a structured framework for cooperation and exchange of information in the field of medical products, including pharmaceutical ingredients, drugs, biological products and medical devices. It aims to promote convergence in regulatory practices, enhance mutual understanding of regulatory systems and facilitate effective and coordinated oversight of medical products, the release stated.

The exchange of the MoU reflects the shared commitment of India and Brazil to ensuring the availability of safe, effective and quality-assured medicines and medical products for their populations. The agreement is also expected to contribute to strengthening supply chains, encouraging regulatory best practices and supporting access to affordable healthcare solutions.

The MoU between CDSCO and ANVISA builds upon the broader India-Brazil cooperation in the health sector and complements existing institutional mechanisms for bilateral engagement. It underscores the growing collaboration between the two countries in health, pharmaceuticals and medical technologies, particularly in the context of their shared priorities as leading Global South partners.

Through this MoU, both sides reaffirmed their intent to work closely in areas such as information sharing, regulatory capacity building, and cooperation in matters related to pharmaceutical and medical product regulation, in accordance with their respective national laws and regulations.

The exchange of the MoU is expected to further strengthen India-Brazil relations and open new avenues for collaboration in the health and pharmaceutical sectors, contributing to improved public health outcomes in both countries.

Brazilian President Luiz Inacio Lula da Silva arrived in India on February 18. During the period February 19-20 participated in the India AI Impact Summit. This is President Lula's fifth visit to India as President of Brazil. The visit comes seven months after the state visit of PM Modi to Brasilia on July 8, 2025.

- ANI

Share this article:

Reader Comments

S
Sarah B
Great news for public health cooperation. India's strength in generic medicines combined with Brazil's experience in universal healthcare systems can create powerful synergies. Hope this leads to faster approvals for life-saving drugs.
V
Vikram M
Strong move by both Global South leaders. This kind of collaboration reduces our dependency on Western regulatory frameworks. Let's hope the execution is as good as the intent. The focus should remain on patient safety and affordability, not just trade volumes.
P
Priya S
My father works in a medical device manufacturing unit in Gujarat. He says alignment with international standards is a constant challenge. If this MoU simplifies processes and builds trust, it could mean more business and more jobs here. Fingers crossed!
R
Rohit P
Good initiative, but I hope our own CDSCO gets strengthened in the process. We still have issues with drug quality and fake medicines within India. Learning from ANVISA's systems should help us improve domestic regulation too. The benefits must trickle down to the common man.
M
Michael C
As someone who follows global health policy, this is a significant development. Two major democracies with large populations aligning on medical regulation sets a powerful example. Collaboration on vaccine and API supply chain resilience would be a logical next step.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50